Stocks and Investing Stocks and Investing
Mon, March 7, 2022

Salveen Richter Maintained (AGIO) at Strong Sell with Decreased Target to $23 on, Mar 7th, 2022


Published on 2024-10-27 19:58:38 - WOPRAI, Salveen Richter
  Print publication without navigation


Salveen Richter of Goldman Sachs, Maintained "Agios Pharmaceuticals, Inc." (AGIO) at Strong Sell with Decreased Target from $37 to $23 on, Mar 7th, 2022.

Salveen has made no other calls on AGIO in the last 4 months.



There are 5 other peers that have a rating on AGIO. Out of the 5 peers that are also analyzing AGIO, 1 agrees with Salveen's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Andrew Berens of "SVB Leerink" Maintained at Hold with Decreased Target to $30 on, Tuesday, February 22nd, 2022


These are the ratings of the 4 analyists that currently disagree with Salveen


  • Michael King of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $96 on, Thursday, March 3rd, 2022
  • Kennen MacKay of "RBC Capital" Maintained at Buy with Increased Target to $67 on, Friday, February 25th, 2022
  • John Newman of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $44 on, Wednesday, February 16th, 2022
  • Greg Harrison of "B of A Securities" Initiated at Strong Buy and Held Target at $54 on, Friday, December 3rd, 2021

Contributing Sources